Login to Your Account



Earnings Roundup


Wednesday, February 15, 2012
• Seattle Genetics Inc., of Bothell, Wash., reported $33.2 million in fourth-quarter net product sales for lymphoma drug Adcetris (brentuximab vedotin), beating analyst estimates of $25.7 million. Sales for the year were $43.2 million. Net loss for the fourth quarter was $27.2 million, or 24 cents per share, while net loss for the year was $152 million, or $1.34 per share.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription